Logo image of CLDX

CELLDEX THERAPEUTICS INC (CLDX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CLDX - US15117B2025 - Common Stock

27.51 USD
-0.43 (-1.54%)
Last: 12/12/2025, 4:30:00 PM
27.51 USD
0 (0%)
After Hours: 12/12/2025, 4:30:00 PM
Fundamental Rating

4

Taking everything into account, CLDX scores 4 out of 10 in our fundamental rating. CLDX was compared to 531 industry peers in the Biotechnology industry. CLDX has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, CLDX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLDX has reported negative net income.
In the past year CLDX has reported a negative cash flow from operations.
In the past 5 years CLDX always reported negative net income.
CLDX had a negative operating cash flow in each of the past 5 years.
CLDX Yearly Net Income VS EBIT VS OCF VS FCFCLDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -34.63%, CLDX is in the better half of the industry, outperforming 62.71% of the companies in the same industry.
With a decent Return On Equity value of -37.52%, CLDX is doing good in the industry, outperforming 71.94% of the companies in the same industry.
Industry RankSector Rank
ROA -34.63%
ROE -37.52%
ROIC N/A
ROA(3y)-27.38%
ROA(5y)-24.67%
ROE(3y)-29.51%
ROE(5y)-26.78%
ROIC(3y)N/A
ROIC(5y)N/A
CLDX Yearly ROA, ROE, ROICCLDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CLDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLDX Yearly Profit, Operating, Gross MarginsCLDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

8

2. Health

2.1 Basic Checks

CLDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CLDX has been increased compared to 1 year ago.
CLDX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CLDX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CLDX Yearly Shares OutstandingCLDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CLDX Yearly Total Debt VS Total AssetsCLDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

CLDX has an Altman-Z score of 18.24. This indicates that CLDX is financially healthy and has little risk of bankruptcy at the moment.
CLDX has a better Altman-Z score (18.24) than 87.57% of its industry peers.
There is no outstanding debt for CLDX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.24
ROIC/WACCN/A
WACC8.78%
CLDX Yearly LT Debt VS Equity VS FCFCLDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

CLDX has a Current Ratio of 13.01. This indicates that CLDX is financially healthy and has no problem in meeting its short term obligations.
CLDX's Current ratio of 13.01 is amongst the best of the industry. CLDX outperforms 87.95% of its industry peers.
CLDX has a Quick Ratio of 13.01. This indicates that CLDX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 13.01, CLDX belongs to the top of the industry, outperforming 87.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.01
Quick Ratio 13.01
CLDX Yearly Current Assets VS Current LiabilitesCLDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for CLDX have decreased strongly by -31.52% in the last year.
Looking at the last year, CLDX shows a very negative growth in Revenue. The Revenue has decreased by -73.94% in the last year.
Measured over the past years, CLDX shows a quite strong growth in Revenue. The Revenue has been growing by 14.48% on average per year.
EPS 1Y (TTM)-31.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.81%
Revenue 1Y (TTM)-73.94%
Revenue growth 3Y14.72%
Revenue growth 5Y14.48%
Sales Q2Q%-100%

3.2 Future

CLDX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.66% yearly.
The Revenue is expected to grow by 141.74% on average over the next years. This is a very strong growth
EPS Next Y-52.04%
EPS Next 2Y-35.06%
EPS Next 3Y-24.43%
EPS Next 5Y7.66%
Revenue Next Year-58.63%
Revenue Next 2Y-29.63%
Revenue Next 3Y14.8%
Revenue Next 5Y141.74%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CLDX Yearly Revenue VS EstimatesCLDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
CLDX Yearly EPS VS EstimatesCLDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 10 -10 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLDX Price Earnings VS Forward Price EarningsCLDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLDX Per share dataCLDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

A cheap valuation may be justified as CLDX's earnings are expected to decrease with -24.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-35.06%
EPS Next 3Y-24.43%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLDX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELLDEX THERAPEUTICS INC

NASDAQ:CLDX (12/12/2025, 4:30:00 PM)

After market: 27.51 0 (0%)

27.51

-0.43 (-1.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners110.56%
Inst Owner Change3.15%
Ins Owners0.21%
Ins Owner Change-0.08%
Market Cap1.83B
Revenue(TTM)2.60M
Net Income(TTM)-224.53M
Analysts80.91
Price Target54.21 (97.06%)
Short Float %13.35%
Short Ratio10.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.66%
Min EPS beat(2)-9.94%
Max EPS beat(2)2.62%
EPS beat(4)2
Avg EPS beat(4)-1.82%
Min EPS beat(4)-9.94%
Max EPS beat(4)5.21%
EPS beat(8)5
Avg EPS beat(8)2.6%
EPS beat(12)8
Avg EPS beat(12)1.58%
EPS beat(16)9
Avg EPS beat(16)0.1%
Revenue beat(2)0
Avg Revenue beat(2)-64.46%
Min Revenue beat(2)-100%
Max Revenue beat(2)-28.92%
Revenue beat(4)1
Avg Revenue beat(4)-40.13%
Min Revenue beat(4)-100%
Max Revenue beat(4)3.25%
Revenue beat(8)4
Avg Revenue beat(8)76.62%
Revenue beat(12)7
Avg Revenue beat(12)112.53%
Revenue beat(16)8
Avg Revenue beat(16)72.64%
PT rev (1m)-0.53%
PT rev (3m)-4.45%
EPS NQ rev (1m)-7.68%
EPS NQ rev (3m)-8.16%
EPS NY rev (1m)-4.82%
EPS NY rev (3m)-5.08%
Revenue NQ rev (1m)31.76%
Revenue NQ rev (3m)6.94%
Revenue NY rev (1m)-21.89%
Revenue NY rev (3m)-32.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 703.09
P/FCF N/A
P/OCF N/A
P/B 3.06
P/tB 3.2
EV/EBITDA N/A
EPS(TTM)-3.38
EYN/A
EPS(NY)-4.47
Fwd EYN/A
FCF(TTM)-2.73
FCFYN/A
OCF(TTM)-2.7
OCFYN/A
SpS0.04
BVpS9
TBVpS8.6
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -34.63%
ROE -37.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.38%
ROA(5y)-24.67%
ROE(3y)-29.51%
ROE(5y)-26.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.71%
Cap/Sales 84.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.01
Quick Ratio 13.01
Altman-Z 18.24
F-Score2
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)61.32%
Cap/Depr(5y)52.82%
Cap/Sales(3y)43.76%
Cap/Sales(5y)35.81%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-57.81%
EPS Next Y-52.04%
EPS Next 2Y-35.06%
EPS Next 3Y-24.43%
EPS Next 5Y7.66%
Revenue 1Y (TTM)-73.94%
Revenue growth 3Y14.72%
Revenue growth 5Y14.48%
Sales Q2Q%-100%
Revenue Next Year-58.63%
Revenue Next 2Y-29.63%
Revenue Next 3Y14.8%
Revenue Next 5Y141.74%
EBIT growth 1Y-47.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-36.78%
EBIT Next 3Y-21.03%
EBIT Next 5YN/A
FCF growth 1Y-85.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-85.95%
OCF growth 3YN/A
OCF growth 5YN/A

CELLDEX THERAPEUTICS INC / CLDX FAQ

Can you provide the ChartMill fundamental rating for CELLDEX THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 4 / 10 to CLDX.


What is the valuation status for CLDX stock?

ChartMill assigns a valuation rating of 0 / 10 to CELLDEX THERAPEUTICS INC (CLDX). This can be considered as Overvalued.


What is the profitability of CLDX stock?

CELLDEX THERAPEUTICS INC (CLDX) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for CLDX stock?

The Earnings per Share (EPS) of CELLDEX THERAPEUTICS INC (CLDX) is expected to decline by -52.04% in the next year.